Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:6.2.1.1 (
ACS
)
78,556
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Understanding the mode of action (MOA) of many natural products can be puzzling with mechanistic clues that seem to lack a common thread. One such puzzle lies in the evaluation of the antitumor properties of the natural product withaferin A (WFA). A variety of seemingly unrelated pathways have been identified to explain its activity, suggesting a lack of selectivity. We now show that WFA acts as an inhibitor of the chaperone,
p97
, both in vitro and in cell models in addition to inhibiting the proteasome in vitro. Through medicinal chemistry, we have refined the activity of WFA toward
p97
and away from the proteasome. Subsequent studies indicated that these WFA analogs retained
p97
activity and cytostatic activity in cell models, suggesting that the modes of action reported for WFA could be connected by proteostasis modulation. Through this endeavor, we highlight how the parallel integration of medicinal chemistry with chemical biology offers a potent solution to one of natures' intriguing molecular puzzles.
ACS
Chem Biol 2015 Aug 21
PMID:Withaferin A Analogs That Target the AAA+ Chaperone p97. 2600 19
Exploratory SAR studies of a new phenyl indole chemotype for
p97
inhibition revealed C-5 indole substituent effects in the ADPGlo assay that did not fully correlate with either electronic or steric factors. A focused series of methoxy-, trifluoromethoxy-, methyl-, trifluoromethyl-, pentafluorosulfanyl-, and nitro-analogues was found to exhibit IC50s from low nanomolar to double-digit micromolar. Surprisingly, we found that the trifluoromethoxy-analogue was biochemically a better match of the trifluoromethyl-substituted lead structure than a pentafluorosulfanyl-analogue. Moreover, in spite of their almost equivalent strongly electron-depleting effect on the indole core, pentafluorosulfanyl- and nitro-derivatives were found to exhibit a 430-fold difference in
p97
inhibitory activities. Conversely, the electronically divergent C-5 methyl- and nitro-analogues both showed low nanomolar activities.
ACS
Med Chem Lett 2015 Dec 10
PMID:Structure-Activity Study of Bioisosteric Trifluoromethyl and Pentafluorosulfanyl Indole Inhibitors of the AAA ATPase p97. 2671 9
A high-throughput screen to discover inhibitors of
p97
ATPase activity identified an indole amide that bound to an allosteric site of the protein. Medicinal chemistry optimization led to improvements in potency and solubility. Indole amide 3 represents a novel uncompetitive inhibitor with excellent physical and pharmaceutical properties that can be used as a starting point for drug discovery efforts.
ACS
Med Chem Lett 2016 Feb 11
PMID:Allosteric Indole Amide Inhibitors of p97: Identification of a Novel Probe of the Ubiquitin Pathway. 2698 95
The AAA+ ATPase
p97
/VCP adopts at least three conformations that depend on the binding of ADP and ATP and alter the orientation of the N-terminal protein-protein interaction (PPI) domain into "up" and "down" conformations. Point mutations that cause multisystem proteinopathy 1 (MSP1) are found at the interface of the N domain and D1-ATPase domain and potentially alter the conformational preferences of
p97
. Additionally, binding of "adaptor" proteins to the N-domain regulates
p97
's catalytic activity. We propose that
p97
/adaptor PPIs are coupled to
p97
conformational states. We evaluated the binding of nucleotides and the adaptor proteins p37 and p47 to wild-type
p97
and MSP1 mutants. Notably, p47 and p37 bind 8-fold more weakly to the ADP-bound conformation of wild-type
p97
compared to the ATP-bound conformation. However, MSP1 mutants lose this nucleotide-induced conformational coupling because they destabilize the ADP-bound, "down" conformation of the N-domain. Loss in conformation coupling to PPIs could contribute to the mechanism of MSP1.
ACS
Chem Biol 2016 08 19
PMID:p97 Disease Mutations Modulate Nucleotide-Induced Conformation to Alter Protein-Protein Interactions. 2726 71
Optimization of the side-chain of a phenyl indole scaffold identified from a high-throughput screening campaign for inhibitors of the AAA+ ATPase
p97
is reported. The addition of an
N
-alkyl piperazine led to high potency of this series in a biochemical assay, activity in cell-based assays, and excellent pharmaceutical properties. Molecular modeling based on a subsequently obtained cryo-EM structure of
p97
in complex with a phenyl indole was used to rationalize the potency of these allosteric inhibitors.
ACS
Med Chem Lett 2018 Nov 08
PMID:Optimization of Phenyl Indole Inhibitors of the AAA+ ATPase p97. 3042 48
VCP/
p97
belongs to the AAA+ ATPase family and has an essential role in several cellular processes ranging from cell division to protein homeostasis. Compounds targeting
p97
inhibit the main ATPase domain and cause cell death. Here, using PNA-encoded chemical libraries, we have identified two small molecules that target the regulatory domain of
p97
, comprising the N-terminal and the D1 ATPase domains, and do not cause cell death. One molecule,
NW1028
, inhibits the degradation of a
p97
-dependent reporter, whereas the other,
NW1030
, increases it. ATPase assays show that
NW1028
and
NW1030
do not affect the main catalytic domain of
p97
. Mapping of the binding site using a photoaffinity conjugate points to a cleft at the interface of the N-terminal and the D1 ATPase domains. We have therefore discovered two new compounds that bind to the regulatory domain of
p97
and modulate specific
p97
cellular functions. Using these compounds, we have revealed a role for
p97
in the regulation of mitotic spindle orientation in HeLa cells.
ACS
Chem Biol 2020 01 17
PMID:Small-Molecule Modulators of the ATPase VCP/p97 Affect Specific p97 Cellular Functions. 3179 Feb 1